CRISPR Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

CRISPR Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 34.5% en 54.3% per jaar. De winst per aandeel zal naar verwachting groeien met 35.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -9.5% zijn.

Belangrijke informatie

34.5%

Groei van de winst

35.2%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	54.3%
Toekomstig rendement op eigen vermogen	-9.5%
Dekking van analisten	Good
Laatst bijgewerkt	11 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

BRSE:1CG - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	559	-262	-294	-269	16
12/31/2025	138	-446	-370	-347	26
12/31/2024	15	-431	-182	-149	25
9/30/2024	203	-240	-191	-189	N/A
6/30/2024	202	-266	-129	-122	N/A
3/31/2024	272	-217	-169	-159	N/A
12/31/2023	371	-154	-272	-260	N/A
9/30/2023	170	-354	-295	-278	N/A
6/30/2023	170	-416	-362	-343	N/A
3/31/2023	100	-524	-377	-352	N/A
12/31/2022	1	-650	-533	-496	N/A
9/30/2022	14	-681	-509	-468	N/A
6/30/2022	15	-633	-516	-445	N/A
3/31/2022	915	312	414	504	N/A
12/31/2021	915	378	457	539	N/A
9/30/2021	902	412	465	544	N/A
6/30/2021	902	447	502	549	N/A
3/31/2021	1	-392	-309	-287	N/A
12/31/2020	1	-349	-257	-238	N/A
9/30/2020	77	-211	-167	-154	N/A
6/30/2020	289	20	45	55	N/A
3/31/2020	289	46	40	48	N/A
12/31/2019	290	67	50	57	N/A
9/30/2019	213	-11	18	25	N/A
6/30/2019	1	-200	-133	-128	N/A
3/31/2019	2	-185	-121	-117	N/A
12/31/2018	3	-165	-99	-96	N/A
9/30/2018	35	-117	-85	-83	N/A
6/30/2018	37	-91	N/A	-79	N/A
3/31/2018	40	-75	N/A	-69	N/A
12/31/2017	41	-68	N/A	-70	N/A
9/30/2017	11	-51	N/A	-75	N/A
6/30/2017	10	-41	N/A	-71	N/A
3/31/2017	7	-36	N/A	-69	N/A
12/31/2016	5	-23	N/A	-53	N/A
9/30/2016	3	-53	N/A	33	N/A
6/30/2016	2	-44	N/A	40	N/A
3/31/2016	1	-31	N/A	51	N/A
12/31/2015	0	-26	N/A	59	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 1CG de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 1CG de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 1CG de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van 1CG ( 54.3% per jaar) zal naar verwachting sneller groeien dan de markt Swiss ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van 1CG ( 54.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat 1CG binnen 3 jaar verliesgevend zal zijn.

CRISPR Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 23% undervalued

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven